

Author Relationships with Industry and Other Entities (Comprehensive) —2015 ACC Health Policy Statement on Cardiovascular Team-Based Care and the Role of Advanced Practice Providers

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
John E. Brush, Jr. (Co-Chair)	Sentara Healthcare and Eastern Virginia Medical School—Professor of Medicine	None	None	None	None	None	None
Eileen M. Handberg (Co-Chair)	UF Health Shands Hospital—Assistant Professor of Medicine; Director, Clinical Programs	None	None	None	• Gilead	<ul style="list-style-type: none"> • Amarin† • Amgen • AstraZeneca† • Baxter • Catabasis • Cytori • Daiichi Sankyo† • Esperion Therapeutics • Genentech • ISIS Pharmaceuticals • Medtronic • NIH† • Mesoblast • Sanofi Aventis • United Therapeutics • Vessex 	None
Cathleen Biga	Cardiovascular Management of Illinois—President, Chief Executive Officer	• Medaxiom†	None	• Cardiovascular Management of Illinois†	None	<ul style="list-style-type: none"> • Cardiology Advocacy Alliance† • Medaxiom Advisory Board* 	None
Kim K. Birtcher	University of Houston College of Pharmacy —	• Jones & Bartlett	None	None	None	• University of	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
	Clinical Professor; Kelsey-Seybold Clinic, Cardiology Department, Secondary Prevention Lipid Clinic— Clinical Pharmacist	Learning				Houston College of Pharmacy† • Walgreens†	
Alfred A. Bove	Temple University Hospital—Professor of Medicine (Emeritus)	<ul style="list-style-type: none"> • Insight Telehealth, LLC* • World Health Networks, Inc. † 	None	<ul style="list-style-type: none"> • Insight Telehealth, LLC* 	<ul style="list-style-type: none"> • Merck Schering Plough† 	None	None
Paul N. Casale	Lancaster General Health —Chief, Division of Cardiology	None	None	None	None	None	None
Michael G. Clark	Heart Center of North Texas — Physician Assistant General/Preventive Cardiology; Touro University—Adjunct Clinical Associate Professor	None	<ul style="list-style-type: none"> • Abbott Pharma • Astra-Zeneca • Gilead 	None	None	<ul style="list-style-type: none"> • Association of Physician Assistants in Cardiology* 	None
Arthur Garson, Jr.	Texas Medical Center, Houston, TX —Professor Management, Policy and Community Health; Texas Medical Center —Director Health Policy Institute	None	None	None	None	<ul style="list-style-type: none"> • Grand-Aides Foundation* 	None
Jerome L. Hines	Illinois Heart and Vascular— Cardiologist	None	None	None	None	None	None
Jane A. Linderbaum	Mayo Clinic—Assistant Professor of Medicine; AskMayoExpert— Associate Medical Editor	None	None	None	None	None	None
George P. Rodgers	University of Texas, Dell Medical School — Assistant Professor of	None	None	<ul style="list-style-type: none"> • Biophysical Corporation† 	None	<ul style="list-style-type: none"> • Championship Hearts Foundation 	<ul style="list-style-type: none"> • Defendant, Cardiopulmonary arrest, 2013

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
	Medicine					(President)*	
Robert A. Shor	Cardiovascular Group PC, DBA Virginia Heart — Vice-President	None	None	None	None	None	None
Vinod H. Thourani	Emory University — Professor of Surgery	<ul style="list-style-type: none"> • Edwards Lifesciences • Sorin • St. Jude Medical 	None	<ul style="list-style-type: none"> • Apica Cardiovascular* 	<ul style="list-style-type: none"> • Medtronic* 	<ul style="list-style-type: none"> • Boston Scientific 	None
Janet F. Wyman	Henry Ford Hospital— Program Coordinator Center for Structural Heart Disease, Advanced Practice Nurse	None	None	None	None	Michigan Council of Nurse Practitioners*	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees.

* No financial benefit.

† Significant relationship.